NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Region-HCEZ-/5sc6-ey97.

COVID-19 vaccinations administered to Chicago residents by Healthy Chicago Equity Zones (HCEZ) based on the reported address, race-ethnicity, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE).

Healthy Chicago Equity Zones is an initiative of the Chicago Department of Public Health to organize and support hyperlocal, community-led efforts that promote health and racial equity. Chicago is divided into six HCEZs. Combinations of Chicago’s 77 community areas make up each HCEZ, based on geography. For more information about HCEZs including which community areas are in each zone see: https://data.cityofchicago.org/Health-Human-Services/Healthy-Chicago-Equity-Zones/nk2j-663f

Vaccination Status Definitions:

·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine.

·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received.

·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains.

Weekly cumulative totals by vaccination status are shown for each combination of race-ethnicity and age group within an HCEZ. Note that each HCEZ has a row where HCEZ is “Citywide” and each HCEZ has a row where age is "All" so care should be taken when summing rows.

Vaccinations are counted based on the date on which they were administered. Weekly cumulative totals are reported from the week ending Saturday, December 19, 2020 onward (after December 15, when vaccines were first administered in Chicago) through the Saturday prior to the dataset being updated.

Population counts are from the U.S. Census Bureau American Community Survey (ACS) 2017-2021 5-year estimates.

Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity within an HCEZ) who have each vaccination status as of the date, divided by the estimated number of people in that subgroup.

Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group within an HCEZ. All coverage percentages are capped at 99%.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

CDPH uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact its estimates. Data reported in I-CARE only includes doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that can be linked to their record, such as someone receiving a vaccine dose in another state, the number of people with a completed series or a booster dose is underesti

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

NOTE: As of 2/16/2023 this table is no longer being updated. For information on COVID-19 Updated (Bivalent) Booster Coverage, go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Race/8267-bg4w.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by age at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This table shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by race / ethnicity and age group.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races.

A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Race/Ethnicity" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/xkga-ifz3 ), which will not be updated after 5/20/2021 and “COVID-19 Vaccinations by Race / Ethnicity” dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/ybkg-w5x2), which will not be updated after 10/20/2021.

NOTE: After 5/20/2021, this dataset will no longer be updated and will be replaced by the new dataset: "COVID-19 Vaccinations by Race/Ethnicity" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/4z97-pa4q). Cumulative number and percent of people who initiated COVID-19 vaccination and who are fully vaccinated by race/ethnicity for select age groups (ages 16+, ages 65-74, and ages 75+) as reported by providers. Population estimates are based on 2019 CT population estimates. The 2019 CT population data which is the most recent year available. The tables that show the percent vaccinated by town and age group are an exception. These tables use 2014 CT population estimates. This the most recent year for which reliable estimates by town and age are available. A person who has received one dose of any vaccine is considered to have received at least one dose. A person is considered fully vaccinated if they have received 2 doses of the Pfizer or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The number with At Least One Dose and the number Fully Vaccinated add up to more than the total number of doses because people who received the Johnson & Johnson vaccine fit into both categories. In this data, a person with reported Hispanic or Latino ethnicity is considered Hispanic regardless of reported race. The category Unknown includes unknown race and/or ethnicity. The percent of people classified as Other race (not specified) and Multiple race in CT WiZ (for COVID-19 vaccine records and all other vaccine records) are higher than would be expected based on census data. Other race, Multiple race and Unknown include people who should be classified as Asian, Black, Hispanic and White. Therefore, the coverage of these groups may be underestimated and should be interpreted with caution. The estimates for the category Multiple Races are considered unreliable All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

NOTE: As of 2/16/2023, this page is no longer being updated. Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by gender at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. * DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. _ This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated grouped by gender and have additional dose 1 grouped by gender. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Population estimates are based on 2019 CT population estimates. Bivalent booster administrations are not included in the additional dose 1 calculations. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional bivalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. The percent with at least one dose may be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed. Note: As part of continuous data quality improvement efforts, duplicate records

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec.

COVID-19 vaccinations administered to Chicago residents based on home address, as reported by medical providers in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). I-CARE includes doses administered in Illinois and some doses administered outside of Illinois and reported in I-CARE by Illinois providers.

Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine.

·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received.

·People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19.

·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains.

·Total doses administered: Number of all COVID-19 vaccine doses administered.

Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, number of people with a monovalent booster dose, and number of people with a bivalent dose. Cumulative totals are also provided for each measure as of that date. Vaccinations are counted based on the day the vaccine was administered.

Coverage percentages for the City of Chicago are calculated based on cumulative number of people with that vaccination status.

Daily totals of all doses, number of people with at least one vaccine dose, number of people who have completed a vaccine series, number of people with a booster dose, and number of people with a bivalent dose are shown by age group, gender, and race/ethnicity.

Denominators are from the U.S. Census Bureau American Community Survey 1-year estimate for 2019 and can be seen in the Citywide, 2019 row of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa).

The Chicago Department of Health (CDPH) uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense, are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that can be linked to their record, such as someone receiving a vaccine dose in another state, the number of people with a completed series or a booster dose is underestimated. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate first dose records for a person and overestimate of the number of people with at least one dose and underestimate the number of people with a completed series or booster dose.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH.

Numbers in this dataset may differ from other public sources due to when data are reported and how vaccination statuses and City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

As of 10/27/2022, this dataset will no longer update. To continue to access updated vaccination metrics given to SF residents, including newly added bivalent boosters, please navigate to the following page: COVID-19 Vaccinations Given to SF Residents Over Time.

A. SUMMARY This dataset represents the COVID-19 vaccinations given to San Franciscans over time. All vaccines given to people who live in San Francisco are included, no matter where the vaccination took place (the vaccine may have been administered in San Francisco or outside of San Francisco).

B. HOW THE DATASET IS CREATED Information on doses administered to those who live in San Francisco is from the California Immunization Registry (CAIR), run by the California Department of Public Health (CDPH).

C. UPDATE PROCESS Updated daily via automated process

D. HOW TO USE THIS DATASET Different vaccines have different dosage requirements. For example, the Moderna and the Pfizer vaccines require two doses in order for a resident to complete their primary vaccine series (as of December 21, 2021). Each dose is recorded separately in its respective dataset column. Other vaccines, such as Johnson & Johnson, would only require a single dose for a resident to complete their primary vaccine series (as of December 21, 2021). The Pfizer vaccine for children under 5 requires three separate doses. Single dose vaccines counts are recorded in a separate column.

Summing the NEW_1ST_DOSES, NEW_2ND_DOSES, NEW_SINGLE_DOSES columns would give you the total count of primary vaccine series doses administered on a given day. To count the number of individuals who have completed their primary vaccine series on a given day, use the NEW_SERIES_COMPLETED column. To count the number of individuals vaccinated (with any primary series dose) for the first time on a given day, use the NEW_RECIPIENTS column.

To count the number of individuals who got a vaccine booster on a given day, use the NEW_BOOSTER_RECIPIENTS column. To count the number of booster doses administered on a given day, use the NEW_BOOSTER_DOSES column. To count the total number of individuals who have received a booster over time, use the CUMULATIVE_BOOSTER_RECIPIENTS column. To count the total number of booster doses that have been administered over time, use the CUMULATIVE_BOOSTER_DOSES column.

In our public dashboards we combine this dataset with the US Census's 2019 five-year American Community Survey population estimates to estimate the percent of San Franciscans vaccinated.

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-ZIP-Code/2ani-ic5x. NOTE, 3/30/2023: We have added columns for bivalent (updated) doses to this dataset. We have also added age group columns for 0-17 and 18-64 and stopped updating the 5+ and 12+ columns, although previously published values remain for those columns. COVID-19 vaccinations administered to Chicago residents based on the home ZIP Code of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). The ZIP Code where a person lives is not necessarily the same ZIP Code where the vaccine was administered. Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ·People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. ·Total doses administered: Number of all COVID-19 vaccine doses administered. Data Notes: Daily counts are shown for the total number of doses administered, number of people with at least one vaccine dose, number of people who have a completed vaccine series, and number of people who have received a bivalent dose. Cumulative totals for each measure as of that date are also provided. Vaccinations are counted based on the day the vaccine was administered. Coverage percentages are calculated based on cumulative number of people who have received at least one vaccine dose, cumulative number of people who have a completed vaccine series, and cumulative number of people who have received a bivalent dose in each ZIP Code. Population counts are from the U.S. Census Bureau American Community Survey 2015-2019 5-year estimates and can be seen in the ZIP Code, 2019 rows of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa). Actual counts may exceed population estimates and lead to >100% coverage, especially in areas with small population sizes. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination which may lead to over or under estimates of vaccination coverage by geography.  All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19. Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

Note: As of 1/22/25, this dataset is no longer updated. This dataset reports the number of people vaccinated by New York providers with at least one dose and with a complete COVID-19 vaccination series overall since December 14, 2020. Currently, three COVID-19 vaccines have been authorized for emergency use by the FDA and approved by New York State's independent Clinical Advisory Task Force: one that was developed by Pfizer and BioNTech, a second that was developed by Moderna and a third that was developed by Janssen/Johnson & Johnson. New York providers include hospitals, mass vaccination sites operated by the State or local governments, pharmacies, and other providers registered with the state to serve as points of distribution. This dataset is created by the New York State Department of Health from data reported to the New York State Immunization Information System (NYSIIS) and the New York City Citywide Immunization Registry (NYC CIR). NYSIIS and CIR are confidential, secure, web-based systems that collect and maintain immunization information in one consolidated record for persons of all ages in NYS governed by Public Health Law 2168. Health care providers are required, by law, to enter all vaccines administered to children up to age 19. Immunizations administered to adults 19 and older may be reported with consent. New York State Department of Health requires all New York State vaccination providers to report all COVID-19 vaccination administration data to NYSIIS and NYC CIR within 24 hours of administration. Vaccination data by age is based on address data reported to NYSIIS and NYC CIR by the providers administering vaccines. Age is calculated by subtracting the dob from the date of vaccination. Note that COVID-19 vaccine availability greatly expanded for the different age groups over the period of time this dataset covers. This data does not include vaccine administered through Federal entities or performed outside of New York State to New York residents. NYSIIS and CIR data is used for age group statistics. This dataset is updated weekly.

NOTE: As of 4/15/2021, this dataset will no longer be updated and will be replaced by two new datasets: 1) "COVID-19 Vaccinations by Town" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town/x7by-h8k4) and "COVID-19 Vaccinations by Town and Age Group" (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Town-and-Age-Group/gngw-ukpw).

A summary of COVID-19 vaccination coverage in Connecticut by town. Records without an address could not be included in town vaccine coverage estimates. Total population estimates are based on 2019 data.

A person who has received one dose of any vaccine is considered to have received at least one dose. A person is considered fully vaccinated if they have received 2 doses of the Pfizer or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The number with At Least One Dose and the number Fully Vaccinated add up to more than the total number of doses because people who received the Johnson & Johnson vaccine fit into both categories.

SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. Towns with a "yes" in the "Has SVI tract >0.75" field are those that have at least one census tract that is in the top quartile of vulnerability (e.g., a high-need area). 34 towns in Connecticut have at least one census tract in the top quartile for vulnerability.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

NOTE: As of 2/16/2023, this page is not being updated. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 grouped by whether they live in an SVI Priority Zip Code. People with an out-of-state zip code are excluded from this analysis. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary vaccine series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional dose of COVID-19 vaccine is considered to have had additional dose 1. The additional monovalent dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. SVI scores were calculated for each zip code in CT. The zip codes in the top 20% were designated as SVI Priority Zip Codes. Percentages are based on 2018 zip code population data supplied by ESRI corporation. The percent with at least one dose many be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ. Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

NOTE: As of 2/16/2023, this page is not being updated. For data on updated (bivalent) COVID-19 booster vaccination click here: https://app.powerbigov.us/view?r=eyJrIjoiODNhYzVkNGYtMzZkMy00YzA3LWJhYzUtYTVkOWFlZjllYTVjIiwidCI6IjExOGI3Y2ZhLWEzZGQtNDhiOS1iMDI2LTMxZmY2OWJiNzM4YiJ9 This table shows the number and percent of people that have initiated COVID-19 vaccination and are fully vaccinated by CT census tract (including residents of all ages). It also shows the number of people who have not received vaccine and who are not yet fully vaccinated. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The percent with at least one dose many be over-estimated and the percent fully vaccinated may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Population data obtained from the 2019 Census ACS (www.census.gov) Geocoding is used to determine the census tract in which a person lives. People for who a census tract cannot be determined based on available address data are not included in this table. DPH recommends that these data are primarily used to identify areas that require additional attention rather than to establish and track the exact level of vaccine coverage. Census tract coverage estimates can play an important role in planning and evaluating vaccination strategies. However, inaccuracies in the data that are inherent to population surveillance may be magnified when analyses are performed down to the census tract level. We make every effort to provide accurate data, but inaccuracies may result from things like incomplete or inaccurate addresses, duplicate records, and sampling error in the American Community Survey that is used to estimate census tract population size and composition. These things may result in overestimates or underestimates of vaccine coverage. Some census tracts are suppressed. This is done if the number of people vaccinated is less than 5 or if the census population estimate is considered unreliable (coefficient of variance > 30%). Coverage estimates over 100% are shown as 100%. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records currently reported to CT WiZ. Caution should be used when interpreting coverage estimates in towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town. As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021. As of 1/13/2021, census tract level data are provider by town for all ages. Data by age group is no longer available.

NOTE: As of 2/16/2023, this table is not being updated. For data on COVID-19 updated (bivalent) booster coverage by town please to go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh. This table shows the number and percent of residents of each CT town that have initiated COVID-19 vaccination, are fully vaccinated and who have received additional dose 1. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Percentages are calculated using 2019 census data (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-Town-and-County-Population-for-Connecticut). Town of residence is verified by geocoding the reported address and then mapping it to a town using municipal boundaries. If an address cannot be geocoded, the reported town is used, if available. People for whom an address is not currently available are shown in this table as “Address pending validation”. Out-of-state residents vaccinated by CT providers are excluded from the table. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated when records for an individual cannot be linked because of differences in how names or date of birth are reported. Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town. SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, ho

NOTE: As of 2/16/2023, this page is no longer being updated. This table shows the number and percent of people that have initiated COVID-19 vaccination and are fully vaccinated by race / ethnicity and town. It includes people of all ages. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple race. A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the exclusion of records classified as NH Unknown Race or NH Other Race. Town of residence is verified by geocoding the reported address and then mapping it a town using municipal boundaries. If an address cannot be geocoded, the reported town is used. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census) or potential data reporting errors. The population denominators for these town- and age-specific coverage estimates are based on 2014 census estimates. This is the most recent year for which reliable town- and age-specific estimates are available. (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Town-Population-with-Demographics). Changes in the size and composition of the population between 2014 and 2021 may results in inaccuracy in vaccine coverage estimates. For example, the size of the Hispanic population may be underestimated in a town given the reported increase in the size of the Hispanic population between the 2010 and 2020 censuses resulting in inflated vaccine coverage estimates. The 2014 census data are grouped in 5-year age bands. For vaccine coverage age groupings not consistent with a standard 5-year age band, each age was assumed to be 20% of the total within a 5-year age band. However, given the large deviation from this assumption for Mansfield because of the presence of the University of Connecticut, the age distribution observed in the 2010 census for the age bands 15 to 19 and 20 to 24 was used to estimate the population denominators. This table does not included doses administered to CT residents by out-of-state providers or by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) because they are not yet reported to CT WiZ (the CT immunization Information System). It is expected that these data will be added in the future. Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while study

A phase 1/2, open-label clinical trial in individuals, 18 years of age and older, who are in good health, have no known history of Coronavirus Disease 2019 (COVID-19) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and meet all other eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of a delayed (>/=12 weeks) vaccine boost on a range of Emergency Use Authorization (EUA)-dosed COVID-19 vaccines (mRNA-1273, and mRNA-1273.211 manufactured by ModernaTX, Inc.; BNT162b2 manufactured by Pfizer/BioNTech; or Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson). This is an adaptive design and may add arms (and increase sample size) as vaccines are awarded EUA and/or variant lineage spike vaccines are manufactured or become available. Enrollment will occur at up to twelve domestic clinical research sites.

This study includes two cohorts. Cohort 1 will include approximately 880 individuals (50 subjects/group; Groups 1E-11E) greater than 18 years of age and older, stratified into two age strata (18-55 years and >/=56 years) who previously received COVID-19 vaccine at Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100 mcg dose, two vaccinations of BNT162b2 at the 30 mcg dose, or one vaccination of Ad26.COV2.S at the 5x10^10 vp dose). Groups 15E-17E will enroll 60 subjects, split (approximately evenly) between age strata as able. Those subjects will be offered enrollment into this study >/=12 weeks after they received the last dose of their EUA vaccine. Subjects will receive a single open-label intramuscular (IM) injection of the designated delayed booster vaccine and will be followed through 12 months after vaccination: 1) Group 1E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp followed by a 100-mcg dose of mRNA-1273, Group 4E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 7E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp followed by a 30-mcg dose of BNT162b2, Group 10E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp followed by a 100-mcg dose of mRNA-1273.211; Group 12E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp followed by a 50-mcg dose of mRNA-1273; Group 15E - previously EUA-dosed vaccination with Janssen (two doses for Group 15E) - Ad26.COV2.S at 5x1010 vp followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV-2 rS vaccine with 50 mcg Matrix-M); 2) Group 2E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 100-mcg dose of mRNA-1273, Group 5E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 8E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 13E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 50-mcg dose of mRNA-1273; Group 16E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M); 3) Group 3E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273. Group 6E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 9E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 11E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273.211. Group 14E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 50-mcg dose of mRNA-1273, Group 17E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M).

A telephone visit will occur one week after each primary EUA vaccination and one week after the booster dose. In person follow-up visits will occur on 14 days following completion of EUA vaccinations and on days 14, and 28 days after the booster dose, as well as 3, 6, and 12 months post the booster vaccination. Additional pools of subjects can be included if needed as additional COVID-19 vaccines are awarded EUA.

The primary objectives of this study are 1) to evaluate the safety and reactogenicity of delayed heterologous or homologous vaccine doses after EUA dosed vaccines, and 2) to evaluate the breadth of the humoral immune responses of heterologous and homologous delayed boost regimens following EUA dosing.

*** The County of Santa Clara Public Health Department discontinued updates to the COVID-19 data tables effective June 30, 2025. The COVID-19 data tables will be removed from the Open Data Portal on December 30, 2025. For current information on COVID-19 in Santa Clara County, please visit the Respiratory Virus Dashboard [sccphd.org/respiratoryvirusdata]. For any questions, please contact phinternet@phd.sccgov.org ***

The dataset provides number of county residents who are booster vaccinated by age group. Number of people vaccinated (completed primary series) is the number of county residents who either received a vaccine requiring a single dose (Janssen/Johnson & Johnson) or received the second dose of a vaccine requiring two doses (Pfizer or Moderna). Source: California Immunization Registry. This table is updated Monday-Friday and will not be updated on holidays.

Counties are experiencing temporary fluctuations in vaccination data received from the State of California due to a data reconciliation process involving integration of vaccination data systems by the State. The data reconciliation process and associated fluctuations in county vaccination are expected to be resolved by May 2022

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be updated as more jurisdictions participate.

Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with at least a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6-12 months, half of the single-year population counts for ages <12 months were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred.

Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage.

Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated without an updated (bivalent) booster dose) or vaccinated with an updated (bivalent) booster dose.

Archive: An archive of historic data, including April 3, 2021-September 24, 2022 and posted on October 21, 2022 is available on data.cdc.gov. The analysis by vaccination status (unvaccinated and at least a primary series) for 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a. The analysis for one booster dose (unvaccinated, primary series only, and at least one booster dose) in 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm. The analysis for two booster doses (unvaccinated, primary series only, one booster dose, and at least two booster doses) in 28 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/ukww-au2k.

References

Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290.

Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152

Content

Stock data of the following companies from Oct 2019 is included in this dataset. (BioNTech , Moderna , Johnson & Johnson , Inovio Pharmaceuticals, Sinovac , Sinopharm , Novavax ,Astrazeneca(Oxford)) (The date 2019 was chosen because few companies got IPO just in 2019)

Inspiration

To do more analysis on the performance of the companies with the influence of covid vaccine.

End note

Please let me know if any more companies are to be included or any changes have to be made to improve the quality of the dataset in the discussion section.